← All organizations
Highest phase reached
Phase 2
First clinical trial
Jun 1, 2005Last known activity
Feb 21, 2018
Acquired by Opko on Jun 30, 2016
Timeline
1980s
- Jun 1, 1987
Transition Therapeutics— Founded
2010s
- Jun 30, 2016
Opko— Acquired By
Drugs by trial phase (12 distinct, 13 trials)
Phase 2 (7 own, 0 via acquisition)
Phase 1 (5 own, 0 via acquisition)
Indications
Studied for
- Aggression
- Alzheimer Disease
- Brain Injuries
- Brain Injuries, Traumatic
- Dementia
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
- Disease
- Down Syndrome
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis C, Chronic
- Hepatitis, Chronic
- Hepatitis, Viral, Human
- Hyperplasia
- Prostatic Hyperplasia
- Psychomotor Agitation
- Signs and Symptoms
- Syndrome
Recent trials (19)
- NCT03297398Lead sponsorPhase 2Feb 21, 2018
- NCT01791725Lead sponsorPhase 2Sep 1, 2013
- NCT01766336Lead sponsorPhase 2Jan 1, 2013
- NCT01735630Lead sponsorPhase 2Nov 1, 2012
- NCT01674010Lead sponsorPhase 2Aug 1, 2012
- NCT01357421Lead sponsorPhase 1May 1, 2011
- NCT01357421Study directorPhase 1May 1, 2011
- NCT00934050Lead sponsorPhase 2Jun 1, 2009
- NCT00934050CollaboratorPhase 2Jun 1, 2009
- NCT00853151CollaboratorPhase 1Feb 1, 2009
- NCT00743002Lead sponsorPhase 2Aug 1, 2008
- NCT00568776CollaboratorPhase 2Dec 1, 2007
- NCT00568776Lead sponsorPhase 2Dec 1, 2007
- NCT00239187Study directorPhase 1Sep 1, 2005
- NCT00239187Lead sponsorPhase 1Sep 1, 2005
Details
- Founded
- Toronto, CA Jun 1, 1987
- Last known activity
- Feb 21, 2018